Psychedelic Stocks,Shroom News Halucenex Sciences Granted Clinical Trial Authorization by Health Canada By Dennis Mutua March 01, 2022 Life sciences development company focusing on researching novel psychedelic compounds, developing and licensing psychedelic compounds the pharmaceutical and nutraceutical markets Halucenex Sciences Inc. has been granted Clinical T...
Psychedelic Stocks,Shroom News Oregon Psilocybin Advisory Board Votes to Disclose Personal and Financial Conflicts By Dennis Mutua February 25, 2022 The advisory board mandated with drafting the rules for Oregon’s nascent psilocybin industry voted unanimously to adopt a motion that requires all the board members to verbally disclose their personal and financial conflict of i...
Shroom News,Spotlight Stock PharmaTher Granted U.S Patent on Ketamine Formulation By Dennis Mutua February 18, 2022 Clinical-stage biotechnology company focused on research, development and commercialization of novel psychedelic pharmaceuticals PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having received a Ketamine patent by th...
Psychedelic Stocks,Shroom News PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Test Status Epilepticus By Dennis Mutua February 02, 2022 Psychedelic biotechnology company focused on research, development and commercialization of novel psychedelic compounds PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having being granted orphan drug designation (OD...
Psychedelic Stocks,Shroom News Lexston Launches Psychedelic Mushroom Genetic Identification Test By Dennis Mutua January 25, 2022 Biotechnology company engaging in contact based cannabis research and analytical testing to help licensed producers in cultivation, processing and extraction of naturally derived compounds Lexston Life Sciences Corp. (CSE: LEXT) (...
Featured,Shroom News Psygen Granted License to Become First Dedicated Psychedelics Manufacturing Facility in Canada By Dennis Mutua January 21, 2022 Manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications Psygen Labs announced having been granted a dealer’s license by Heath Canada to become Canada’s first dedicated ...
Psychedelic Stocks,Shroom News Numinus Submits Clinical Trial Application For Naturally Extracted Psilocybe Formulation NBIO-01 By Dennis Mutua January 17, 2022 Mental health and wellness company focusing on administering psychedelic medicine with holistic integrated psychotherapy Numinus Wellness Inc. (TSX: NUMI) has submitted clinical trial application (CTA) to Health Canada for the Pha...
Psychedelic Stocks,Shroom News Mydecine Completes Supercomputing AI Modeling for Psychedelic Drug Development By Dennis Mutua January 11, 2022 Biotechnology company specializing in research, development and acceptance of naturally extracted medicine for better clinical trial management and mental health welfare Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) ann...